20-valent pneumococcal conjugate vaccine to enter market
By Whang, byung-woo | translator Alice Kang
24.11.08 05:55:18
가나다라
0
Pfizer’s Prevenar 20 approved on October 30, will be released in the first half of next year
Upgrades from Prevenar 13 to Prevenar 20... threaten the position of the 15-valent vaccine Vaxneuvance
Whether the newly approved vaccines will be registered for pediatric NIPs and their non-reimbursed prices in the adult market will serve as key
The pneumococcal vaccine market, which has shifted with the introduction of a 15-valent vaccine this year, is expected to again face fierce competition with the approval of a new 20-valent vaccine.
Pfizer, which is about to launch a new product, plans to replace the share of its existing product, Prevenar 13 with its new product, Prevenar 20.
In the process, MSD, which has been gaining market share since the launch of Vaxneuvance, will also be facing increasing challenges to secure its sales.
▲(From the left) Product photos of Vaxneuvance and Prevenar 20
According to industry sources on the 7th, the Ministry of Food and Drug Safety recently approved Pfizer's ‘Prevenar 20 Prefilled Syringe' (Prevenar 20).
Preve
Whang, byung-woo(tuai@dailypharm.com)
If you want to see the full article, please JOIN US (click)